论文部分内容阅读
目的:探讨原发性非小细胞肺癌(NSCLC)组织中E-钙粘蛋白(E-cadherin,E-cad)、表皮生长因子受体(Epidermal Growth FactorReceptor,EGFR)和基质金属蛋白酶9(matrix metalloproteinase-9,MMP9)的表达与术后复发及转移的关系。方法:选择临床IB期非小细胞肺癌患者的手术切除标本,其中36例于36个月之内发生复发或转移,30例术后无病生存期超过36个月。采用免疫组织化学方法检测组织中E-cad、EGFR、MMP9的表达情况。结果:36例早转移IB期非小细胞肺癌术后患者的手术标本中,E-cad的异常表达率、EGFR及MMP9的阳性表达率,均明显高于30例非早转移IB期非小细胞肺癌术后患者(P<0.05),且在早转移IB期NSCLC中,三者的表达与病理分级、肿瘤大小有关(P<0.05),与病理类型,肿瘤是否浸润胸膜无关(P>0.05)。结论:对早期肺癌术后病人,检测E-cad、EGFR、MMP9的表达,对判断其恶性程度,提示肿瘤的复发及转移倾向大小,决定术后治疗方案有重要意义。
Objective: To investigate the expression of E-cadherin, epidermal growth factor receptor (EGFR) and matrix metalloproteinase 9 in primary non-small cell lung cancer (NSCLC) -9, MMP9) expression and postoperative recurrence and metastasis. Methods: Surgical specimens from patients with non-small cell lung cancer (NSCLC) of stage IB were selected. Among 36 cases, 36 cases recurred or metastasized within 36 months, and 30 patients had disease-free survival for more than 36 months. Immunohistochemistry was used to detect the expression of E-cad, EGFR and MMP9 in the tissue. Results: The abnormal expression rates of E-cad and the positive rates of EGFR and MMP9 in 36 cases of patients with early stage metastasis of stage IB NSCLC were significantly higher than those of 30 cases of stage IB non-metastatic non-small cell lung cancer (P <0.05), and the expression of the three was related to the pathological grade and the size of tumor (P <0.05), and had no correlation with the pathological type and whether the tumor infiltrated the pleura (P> 0.05) . Conclusion: The expression of E-cad, EGFR and MMP9 in early postoperative lung cancer patients is very important in judging the malignant degree, suggesting the tendency of tumor recurrence and metastasis and determining the postoperative treatment plan.